Literature DB >> 19903428

Managing the risks of IBD therapy.

Cynthia H Seow1, Shanika de Silva, Gilaad G Kaplan, Shane M Devlin, Subrata Ghosh, Remo Panaccione.   

Abstract

Successful management of the patient with inflammatory bowel disease (IBD) involves not only the induction and maintenance of remission, but also the optimization of the benefit-to-risk equation to achieve the greatest gain in quality of life. These risks range from intolerance to prescribed medications to potentially life-threatening sequelae (eg, sepsis) of immune suppression. A proper awareness of risk on the part of the physician and education of the patient can lead to early detection and institution of an appropriate management plan, including risk management and, optimally, primary prevention (eg, prophylactic vaccination). One should take the opportunity regularly to reassess the utility and efficacy of existing therapy, with the provision of ineffective therapies mandating urgent review. Overall, optimal management of the patient with IBD requires open dialogue between clinician and patient so that both are cognizant of the goals, benefits, and potential risks of therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903428     DOI: 10.1007/s11894-009-0077-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  63 in total

1.  American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases.

Authors: 
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

2.  Myopericarditis and mitral insufficiency associated with ulcerative colitis treated with mesalazine.

Authors:  Sara García-Morán; Federico Sáez-Royuela; Juan-Carlos Pérez-Alvarez; Elena Gento; José Téllez
Journal:  Inflamm Bowel Dis       Date:  2006-04       Impact factor: 5.325

Review 3.  Prevention and treatment of osteoporosis in inflammatory bowel disease.

Authors:  Gary R Lichtenstein; Bruce E Sands; Michael Pazianas
Journal:  Inflamm Bowel Dis       Date:  2006-08       Impact factor: 5.325

4.  Liver toxicity of TNFalpha antagonists.

Authors:  Larrey Dominique
Journal:  Joint Bone Spine       Date:  2008-10-26       Impact factor: 4.929

Review 5.  5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Yago González-Lama; José Maté
Journal:  Inflamm Bowel Dis       Date:  2007-05       Impact factor: 5.325

6.  Mesalazine-associated interstitial nephritis.

Authors:  M J World; P E Stevens; M A Ashton; D J Rainford
Journal:  Nephrol Dial Transplant       Date:  1996-04       Impact factor: 5.992

7.  Risk factors for opportunistic infections in patients with inflammatory bowel disease.

Authors:  Murat Toruner; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; Robert Orenstein; William J Sandborn; Jean-Frederic Colombel; Laurence J Egan
Journal:  Gastroenterology       Date:  2008-01-11       Impact factor: 22.682

Review 8.  Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

Authors:  A Fromont; J De Seze; M C Fleury; J F Maillefert; T Moreau
Journal:  Cytokine       Date:  2008-12-23       Impact factor: 3.861

Review 9.  Budesonide for induction of remission in Crohn's disease.

Authors:  Cynthia H Seow; Eric I Benchimol; Anne Marie Griffiths; Anthony R Otley; A Hillary Steinhart
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

10.  Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?

Authors:  M M Elseviers; G D'Haens; E Lerebours; C Plane; J C Stolear; G Riegler; G Capasso; M Van Outryve; P Mishevska-Mukaetova; S Djuranovic; P Pelckmans; M E De Broe
Journal:  Clin Nephrol       Date:  2004-02       Impact factor: 0.975

View more
  4 in total

1.  Treat to Target in Inflammatory Bowel Disease.

Authors:  Peter Bossuyt; Séverine Vermeire
Journal:  Curr Treat Options Gastroenterol       Date:  2016-03

2.  Extracts of Feijoa Inhibit Toll-Like Receptor 2 Signaling and Activate Autophagy Implicating a Role in Dietary Control of IBD.

Authors:  Noha Ahmed Nasef; Sunali Mehta; Penny Powell; Gareth Marlow; Tom Wileman; Lynnette R Ferguson
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

3.  Anti-inflammatory activity of fruit fractions in vitro, mediated through toll-like receptor 4 and 2 in the context of inflammatory bowel disease.

Authors:  Noha Ahmed Nasef; Sunali Mehta; Pamela Murray; Gareth Marlow; Lynnette R Ferguson
Journal:  Nutrients       Date:  2014-11-19       Impact factor: 5.717

Review 4.  Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.

Authors:  Stefano Mazza; Sara Soro; Maria Chiara Verga; Biagio Elvo; Francesca Ferretti; Fabrizio Cereatti; Andrea Drago; Roberto Grassia
Journal:  World J Hepatol       Date:  2021-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.